PL3193929T3 - Schematy leczenia z zastosowaniem przeciwciał anty-nkg2a - Google Patents

Schematy leczenia z zastosowaniem przeciwciał anty-nkg2a

Info

Publication number
PL3193929T3
PL3193929T3 PL15763016T PL15763016T PL3193929T3 PL 3193929 T3 PL3193929 T3 PL 3193929T3 PL 15763016 T PL15763016 T PL 15763016T PL 15763016 T PL15763016 T PL 15763016T PL 3193929 T3 PL3193929 T3 PL 3193929T3
Authority
PL
Poland
Prior art keywords
treatment regimens
nkg2a antibodies
nkg2a
antibodies
regimens
Prior art date
Application number
PL15763016T
Other languages
English (en)
Inventor
Pascale Andre
Mathieu Blery
Carine Paturel
Caroline SOULAS
Nicolaï WAGTMANN
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of PL3193929T3 publication Critical patent/PL3193929T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PL15763016T 2014-09-16 2015-09-15 Schematy leczenia z zastosowaniem przeciwciał anty-nkg2a PL3193929T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462050948P 2014-09-16 2014-09-16
US201462067642P 2014-10-23 2014-10-23
US201462083929P 2014-11-25 2014-11-25
US201462093141P 2014-12-17 2014-12-17
US201462093124P 2014-12-17 2014-12-17
PCT/EP2015/071073 WO2016041947A1 (en) 2014-09-16 2015-09-15 Treatment regimens using anti-nkg2a antibodies
EP15763016.1A EP3193929B1 (en) 2014-09-16 2015-09-15 Treatment regimens using anti-nkg2a antibodies

Publications (1)

Publication Number Publication Date
PL3193929T3 true PL3193929T3 (pl) 2019-12-31

Family

ID=54105801

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15763016T PL3193929T3 (pl) 2014-09-16 2015-09-15 Schematy leczenia z zastosowaniem przeciwciał anty-nkg2a

Country Status (14)

Country Link
US (3) US10676523B2 (pl)
EP (1) EP3193929B1 (pl)
JP (3) JP2017538660A (pl)
KR (1) KR20170068458A (pl)
CN (1) CN107074950A (pl)
AU (2) AU2015316993B2 (pl)
CA (1) CA2959463A1 (pl)
DK (1) DK3193929T3 (pl)
ES (1) ES2742456T3 (pl)
HU (1) HUE044704T2 (pl)
IL (1) IL250672B (pl)
PL (1) PL3193929T3 (pl)
SG (2) SG11201701387SA (pl)
WO (1) WO2016041947A1 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
EP2721068B1 (en) 2011-06-17 2018-12-05 Novo Nordisk A/S Selective elimination of erosive cells
DK3193931T3 (da) 2014-09-16 2020-10-19 Innate Pharma Neutralisering af hæmmende veje i lymfocytter
EP3659625A1 (en) 2014-10-23 2020-06-03 Innate Pharma Treatment of cancers using anti-nkg2a agents
CN107850596B (zh) 2015-07-24 2020-12-04 先天制药公司 用于检测组织浸润nk细胞的方法
PT3405495T (pt) 2016-01-21 2021-05-14 Innate Pharma Neutralização de vias inibidoras em linfócitos
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CA3037851A1 (en) 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELINE BINDING PROTEINS
CN111465614A (zh) * 2017-07-10 2020-07-28 先天制药公司 使用人siglec-9抗体和人nkg2a抗体治疗癌症的组合疗法
WO2019075378A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. B-MATURATION ANTIGEN BINDING PROTEINS
EA202092147A1 (ru) 2018-03-13 2021-03-04 Иннейт Фарма Лечение рака головы и шеи
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
EP3878869A4 (en) * 2018-11-07 2023-04-19 Shanghai Hyamab Biotech Co., Ltd. NKG2A ANTIBODY, METHOD FOR PREPARATION AND USE
CA3119838A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
US20220185895A1 (en) * 2019-03-29 2022-06-16 Dren Bio, Inc. Methods of reducing large granular lymphocyte and natural killer cell levels
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
EP3976831A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
EP4054591A1 (en) 2019-11-04 2022-09-14 Astrazeneca AB Combination therapy for treating cancer
WO2021219048A1 (zh) * 2020-04-30 2021-11-04 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用
MX2023000197A (es) 2020-07-07 2023-02-22 BioNTech SE Arn terapeutico para el cancer positivo para vph.
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
JP2023543835A (ja) 2020-09-30 2023-10-18 ドレン バイオ， インコーポレイテッド 抗ｃｄ９４抗体及びその使用方法
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
EP4267105A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
US20220389100A1 (en) * 2021-06-01 2022-12-08 Symphogen A/S Anti-nkg2a antibodies and compositions
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against CD40 and CD137 in combined cancer therapy
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
AU2005321017B2 (en) 2004-12-28 2011-02-24 Innate Pharma S.A. Monoclonal antibodies against NKG2A
CN101107269B (zh) * 2004-12-28 2012-10-31 依奈特制药公司 抗nkg2a的单克隆抗体
PT2426150T (pt) 2006-06-30 2018-01-22 Novo Nordisk As Anticorpos anti-nkg2a e utilizações dos mesmos
BRPI0908508A2 (pt) 2008-01-24 2016-03-22 Novo Nordisk As anticorpo monoclonal nkg2a anti-humano humanizado
EP2721068B1 (en) 2011-06-17 2018-12-05 Novo Nordisk A/S Selective elimination of erosive cells
DK3193931T3 (da) 2014-09-16 2020-10-19 Innate Pharma Neutralisering af hæmmende veje i lymfocytter
EP3659625A1 (en) 2014-10-23 2020-06-03 Innate Pharma Treatment of cancers using anti-nkg2a agents
PT3405495T (pt) 2016-01-21 2021-05-14 Innate Pharma Neutralização de vias inibidoras em linfócitos

Also Published As

Publication number Publication date
CN107074950A (zh) 2017-08-18
US20170298131A1 (en) 2017-10-19
AU2015316993B2 (en) 2021-03-18
EP3193929A1 (en) 2017-07-26
JP2023055871A (ja) 2023-04-18
KR20170068458A (ko) 2017-06-19
JP2021008487A (ja) 2021-01-28
SG11201701387SA (en) 2017-03-30
JP2017538660A (ja) 2017-12-28
HUE044704T2 (hu) 2019-11-28
EP3193929B1 (en) 2019-06-12
IL250672B (en) 2020-10-29
WO2016041947A1 (en) 2016-03-24
US20210238285A1 (en) 2021-08-05
US20200299383A1 (en) 2020-09-24
US10676523B2 (en) 2020-06-09
CA2959463A1 (en) 2016-03-24
AU2021203744A1 (en) 2021-07-01
DK3193929T3 (da) 2019-08-19
IL250672A0 (en) 2017-04-30
ES2742456T3 (es) 2020-02-14
AU2015316993A1 (en) 2017-03-16
SG10202007781TA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
IL250672B (en) Treatment regimens using anti-nkg2a antibodies
IL250583A0 (en) Anti-tigit antibodies
SG11201703403TA (en) Anti-tim-3 antibodies
SG11201703346PA (en) Anti-tim-3 antibodies
HK1245804A1 (zh) 用於治療pvns的抗csf1r抗體
IL252422A0 (en) Effector-deficient anti-cd32a antibodies
IL273265A (en) New combinations for antigen-based therapy
IL250374B (en) Antibodies against ceramide
PT3101132T (pt) Anticorpo humano anti-transtirretina
PL3180356T3 (pl) Ludzkie przeciwciało anty-fgfr4
IL247988A0 (en) Antibodies against hpa–1a
IL266292A (en) treatment regimens
GB201411027D0 (en) Treatment
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201419092D0 (en) Anti-TIM-3 antibodies
GB201417614D0 (en) Antibodies
GB201414270D0 (en) Antibodies
GB201405775D0 (en) Antibodies
GB201401200D0 (en) Antibodies
GB201413317D0 (en) Atheroscierosis treatment
GB201412411D0 (en) Treatment
GB201412410D0 (en) Treatment
GB201400241D0 (en) Treatment
GB201400235D0 (en) Treatment
GB201400238D0 (en) Treatment